Novavax, Inc. (NASDAQ:NVAX)’s shares jumped 2.89% to $4.27. The company on May 12 announced follow-up data from its dose-ranging Phase 1 clinical trial of its respiratory syncytial virus (RSV) F-protein vaccine in 220 elderly adults (60 years of age and older, with a mean age of 68) that was initiated in October 2012. Novavax, Inc. (NASDAQ:NVAX), weekly performance is 7.26%. On last trading day company shares ended up $4.58. Analysts mean target price for the company is $11.00. Novavax, Inc. (NASDAQ:NVAX), distance from 50-day simple moving average (SMA50) is 2.86%.
Mast Therapeutics Inc (NYSEMKT:MSTX), reported fiscal results for the quarter that ended 31 March 2014. In this period, it made good progress across multiple clinical as well as corporate fronts, including its U.S. expansion of the EPIC, the company’s pivotal Phase III study of MST-188 in sickle-cell disease, and the pipeline expansion with acquisition of its AIR001, a clinical-stage-program. Mast Therapeutics Inc (NYSEMKT:MSTX), advanced 7.54% in last trading session and ended the day on $0.654. MSTX, return on assets is -38.90%. Mast Therapeutics Inc (NYSEMKT:MSTX), quarterly performance is -19.28%.
On May 14, 2014, Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), announced that clinical data on Iclusig (ponatinib) and AP26113, its investigational oral inhibitor of anaplastic lymphoma kinase (ALK), will be presented at the Annual Meeting of the American Society of Clinical Oncology being held in Chicago, May 30 to June 3, 2014. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), shares moved up 3.77% in last trading session and was closed at $6.60, while trading in range of $6.26 – 6.60. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), year to date (YTD) performance is -3.23%.
Gilead Sciences, Inc. (NASDAQ:GILD), announced that its corporate presentation will be webcast from the 2014 UBS Healthcare Conference in New York. Gilead Sciences, Inc. (NASDAQ:GILD), ended the last trading day at $82.05. Company weekly volatility is calculated as 1.98% and price to cash ratio as 18.37. Gilead Sciences, Inc. (NASDAQ:GILD), showed a positive weekly performance of 2.12%.
On May 14, 2014, MannKind Corporation (NASDAQ:MNKD), presented its clinical trials data to an FDA Advisory Panel in April and that panel overwhelmingly recommended AFREZZA for FDA approval. The FDA calendar currently has AFREZZA scheduled for review on July 15th. MannKind and its investors have a lot at stake pending the FDA approval in July. MannKind Corporation (NASDAQ:MNKD), weekly performance is 16.75%. On last trading day company shares ended up $7.39. Analysts mean target price for the company is $8.07. MannKind Corporation (NASDAQ:MNKD), distance from 50-day simple moving average (SMA50) is 20.82%.
Leave a Reply